SG11201701913SA - Treatment of fibrodysplasia ossificans progressiva - Google Patents

Treatment of fibrodysplasia ossificans progressiva

Info

Publication number
SG11201701913SA
SG11201701913SA SG11201701913SA SG11201701913SA SG11201701913SA SG 11201701913S A SG11201701913S A SG 11201701913SA SG 11201701913S A SG11201701913S A SG 11201701913SA SG 11201701913S A SG11201701913S A SG 11201701913SA SG 11201701913S A SG11201701913S A SG 11201701913SA
Authority
SG
Singapore
Prior art keywords
treatment
fibrodysplasia ossificans
ossificans progressiva
progressiva
fibrodysplasia
Prior art date
Application number
SG11201701913SA
Other languages
English (en)
Inventor
Sarah J Hatsell
Aris N Economides
Vincent J Idone
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of SG11201701913SA publication Critical patent/SG11201701913SA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Chemical Or Physical Treatment Of Fibers (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Diaphragms For Electromechanical Transducers (AREA)
SG11201701913SA 2014-09-12 2015-09-14 Treatment of fibrodysplasia ossificans progressiva SG11201701913SA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462049869P 2014-09-12 2014-09-12
US201562141775P 2015-04-01 2015-04-01
PCT/US2015/000100 WO2016039796A2 (fr) 2014-09-12 2015-09-14 Traitement de la fibrodysplasie ossifiante progressive

Publications (1)

Publication Number Publication Date
SG11201701913SA true SG11201701913SA (en) 2017-04-27

Family

ID=54207748

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10201902175RA SG10201902175RA (en) 2014-09-12 2015-09-14 Treatment of fibrodysplasia ossificans progressiva
SG11201701913SA SG11201701913SA (en) 2014-09-12 2015-09-14 Treatment of fibrodysplasia ossificans progressiva

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG10201902175RA SG10201902175RA (en) 2014-09-12 2015-09-14 Treatment of fibrodysplasia ossificans progressiva

Country Status (28)

Country Link
US (3) US20160075772A1 (fr)
EP (2) EP3604335A1 (fr)
JP (1) JP6560341B2 (fr)
KR (1) KR102564079B1 (fr)
CN (1) CN107106648B (fr)
AU (1) AU2015315829B2 (fr)
CA (1) CA2960950C (fr)
CL (2) CL2017000603A1 (fr)
CY (1) CY1122188T1 (fr)
DK (1) DK3191512T3 (fr)
ES (1) ES2739605T3 (fr)
HR (1) HRP20191929T1 (fr)
HU (1) HUE046558T2 (fr)
IL (1) IL251063B (fr)
LT (1) LT3191512T (fr)
MA (1) MA40621B1 (fr)
ME (1) ME03541B (fr)
MX (1) MX2017003175A (fr)
MY (1) MY179654A (fr)
NZ (1) NZ730773A (fr)
PL (1) PL3191512T3 (fr)
PT (1) PT3191512T (fr)
RS (1) RS59412B1 (fr)
SG (2) SG10201902175RA (fr)
SI (1) SI3191512T1 (fr)
TW (1) TWI688402B (fr)
WO (1) WO2016039796A2 (fr)
ZA (1) ZA201702112B (fr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2012339722B2 (en) 2011-11-14 2017-09-14 Regeneron Pharmaceuticals, Inc. Compositions and methods for increasing muscle mass and muscle strength by specifically antagonizing GDF8 and/or Activin A
TW201920262A (zh) 2013-07-30 2019-06-01 美商再生元醫藥公司 抗活化素ａ之抗體及其用途
US20160075772A1 (en) 2014-09-12 2016-03-17 Regeneron Pharmaceuticals, Inc. Treatment of Fibrodysplasia Ossificans Progressiva
KR20180006386A (ko) 2015-04-22 2018-01-17 얼라이브젠 유에스에이 인코포레이티드 신규한 근육 소모 질환 치료용 하이브리드 ａｃｔｒｉｉｂ 리간드 트랩 단백질
EP3415527A1 (fr) * 2017-06-14 2018-12-19 Technische Universität Dresden Utilisation du domaine extracellulaire du récepteur de transfert 2 destiné au diagnostic et au traitement des pathologies sclérosantes primaires et secondaires
CN111787981A (zh) 2018-03-01 2020-10-16 瑞泽恩制药公司 改变身体组成的方法
CA3093205A1 (fr) * 2018-03-05 2019-09-12 Saitama Medical University Composition pharmaceutique pour le traitement ou la prevention de l'ossification heterotopique
CA3099441A1 (fr) * 2018-06-13 2019-12-19 Regeneron Pharmaceuticals, Inc. Modele de rongeur a fibrodysplasie ossifiante progressive
EP3806885A2 (fr) 2018-06-13 2021-04-21 Kymab Limited Traitements, etc
WO2020028831A1 (fr) * 2018-08-02 2020-02-06 Dyne Therapeutics, Inc. Complexes de ciblage musculaire et leurs utilisations pour le traitement de la fibrodysplasie ossifiante progressive
KR20210081324A (ko) 2018-08-02 2021-07-01 다인 세라퓨틱스, 인크. 근육 표적화 복합체 및 안면견갑상완 근육 이영양증을 치료하기 위한 그의 용도
CN113366019A (zh) * 2018-10-23 2021-09-07 科乐斯疗法公司 Alk2抗体及其使用方法
KR20210104744A (ko) * 2018-12-18 2021-08-25 리제너론 파마슈티칼스 인코포레이티드 렙틴 수용체, gdf8 및 액티빈 a에 대한 길항제를 사용하여 체중 및 제지방 근육량을 향상시키기 위한 조성물 및 방법
CN115243763A (zh) * 2020-01-08 2022-10-25 里珍纳龙药品有限公司 治疗进行性骨化性纤维发育不良
WO2021142260A1 (fr) * 2020-01-10 2021-07-15 Dyne Therapeutics, Inc. Complexes de ciblage musculaire et utilisations associées pour la modulation d'acvr1
CN116322768A (zh) * 2020-06-18 2023-06-23 里珍纳龙药品有限公司 激活素a抗体调配物和其使用方法
US11638761B2 (en) 2021-07-09 2023-05-02 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating Facioscapulohumeral muscular dystrophy
CN118176018A (zh) * 2021-09-03 2024-06-11 来凯医药科技(上海)有限公司 抗acvr2a抗体及其用途

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH652145A5 (de) 1982-01-22 1985-10-31 Sandoz Ag Verfahren zur in vitro-herstellung von hybridomen welche humane monoklonale antikoerper erzeugen.
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4634666A (en) 1984-01-06 1987-01-06 The Board Of Trustees Of The Leland Stanford Junior University Human-murine hybridoma fusion partner
US4980286A (en) 1985-07-05 1990-12-25 Whitehead Institute For Biomedical Research In vivo introduction and expression of foreign genetic material in epithelial cells
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
EP0307434B2 (fr) 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Anticorps alteres
US6018026A (en) 1988-01-22 2000-01-25 Zymogenetics, Inc. Biologically active dimerized and multimerized polypeptide fusions
US5567584A (en) 1988-01-22 1996-10-22 Zymogenetics, Inc. Methods of using biologically active dimerized polypeptide fusions to detect PDGF
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5225538A (en) 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
AU633698B2 (en) 1990-01-12 1993-02-04 Amgen Fremont Inc. Generation of xenogeneic antibodies
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
WO1992003918A1 (fr) 1990-08-29 1992-03-19 Genpharm International, Inc. Animaux non humains transgeniques capables de produire des anticorps heterologues
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5871907A (en) 1991-05-15 1999-02-16 Medical Research Council Methods for producing members of specific binding pairs
US5858657A (en) 1992-05-15 1999-01-12 Medical Research Council Methods for producing members of specific binding pairs
EP1400536A1 (fr) 1991-06-14 2004-03-24 Genentech Inc. Procédé pour fabriquer des anticorps humanisés
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
EP0746609A4 (fr) 1991-12-17 1997-12-17 Genpharm Int Animaux transgeniques non humains capables de produire des anticorps heterologues
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
US5837242A (en) 1992-12-04 1998-11-17 Medical Research Council Multivalent and multispecific binding proteins, their manufacture and use
CA2115811A1 (fr) 1993-02-17 1994-08-18 Claus Krebber Methode de selection in vivo de proteines fixatrices de ligands
US5877218A (en) 1994-01-10 1999-03-02 Teva Pharmaceutical Industries, Ltd. Compositions containing and methods of using 1-aminoindan and derivatives thereof and process for preparing optically active 1-aminoindan derivatives
US5834597A (en) 1996-05-20 1998-11-10 Protein Design Labs, Inc. Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same
DE60045319D1 (de) 1999-02-05 2011-01-13 Samsung Electronics Co Ltd Verfahren und Vorrichtung zum Wiederauffinden von Texturbildern
EP1539233B1 (fr) 2001-07-12 2011-04-27 FOOTE, Jefferson Anticorps super humanises
CA2550551C (fr) 2004-01-16 2013-10-29 Regeneron Pharmaceuticals, Inc. Polypeptides hybrides capables d'activer des recepteurs
CA2574777C (fr) 2004-07-23 2015-09-01 Acceleron Pharma Inc. Polypeptides du recepteur actrii, procedes et compositions correspondants
US8128933B2 (en) 2005-11-23 2012-03-06 Acceleron Pharma, Inc. Method of promoting bone growth by an anti-activin B antibody
US8859752B2 (en) * 2006-04-18 2014-10-14 The Trustees Of The University Of Pennsylvania SIRNA-based therapy of Fibrodyplasia Ossificans Progressiva (FOP)
BRPI0714893A2 (pt) * 2006-09-05 2013-05-28 Medarex Inc anticorpo monoclonal isolado ou uma porÇço de ligaÇço ao seu antÍgeno, um fragmento de anticorpo, um anticorpo mimÉtico, imunoconjugado, composiÇço molÉcula de Ácido nuclÉico isolada, vetor de expressço, cÉlula hospedeira, mÉtodo para preparar um anticorpo anti-bmp2 ou anti-bmp4, mÉtodo para tratar ou prevenir uma doenÇa associada com formaÇço àssea normal e ossificaÇço, hibridoma e metodo para preparar o anticorpo
CL2007002567A1 (es) * 2006-09-08 2008-02-01 Amgen Inc Proteinas aisladas de enlace a activina a humana.
TW202021980A (zh) * 2007-02-02 2020-06-16 美商艾瑟勒朗法瑪公司 衍生自ActRIIB的變體與其用途
CN103877564A (zh) 2007-09-18 2014-06-25 阿塞勒隆制药公司 活化素-actriia拮抗剂和减少或抑制fsh分泌的用途
JP5270913B2 (ja) 2007-12-26 2013-08-21 サンゴバン・ティーエム株式会社 高電気抵抗高ジルコニア鋳造耐火物
JP5638961B2 (ja) * 2008-03-13 2014-12-10 ザ ジェネラル ホスピタル コーポレイション Ｂｍｐシグナル伝達経路のインヒビター
WO2009137075A1 (fr) 2008-05-06 2009-11-12 Acceleron Pharma Inc. Anticorps anti-activine et leurs utilisations pour promouvoir la croissance osseuse
JP5941842B2 (ja) * 2010-06-18 2016-06-29 Ｌｓｉｐファンド運営合同会社 優性アレル発現抑制剤
WO2013063536A1 (fr) * 2011-10-27 2013-05-02 Acceleron Pharma, Inc. AGENTS DE LIAISON À ActRIIB ET UTILISATIONS DE CEUX-CI
AU2012339722B2 (en) * 2011-11-14 2017-09-14 Regeneron Pharmaceuticals, Inc. Compositions and methods for increasing muscle mass and muscle strength by specifically antagonizing GDF8 and/or Activin A
WO2014051109A1 (fr) 2012-09-28 2014-04-03 協和発酵キリン株式会社 Anticorps anti-bmp9 humain et agent thérapeutique pour une maladie d'ossification ectopique contenant ledit anticorps comme principe actif
TWI682941B (zh) 2013-02-01 2020-01-21 美商再生元醫藥公司 含嵌合恆定區之抗體
TW201920262A (zh) * 2013-07-30 2019-06-01 美商再生元醫藥公司 抗活化素ａ之抗體及其用途
WO2015152183A1 (fr) * 2014-03-31 2015-10-08 大日本住友製薬株式会社 Agent prophylactique et agent thérapeutique pour la fibrodysplasie ossifiante progressive
US20160075772A1 (en) 2014-09-12 2016-03-17 Regeneron Pharmaceuticals, Inc. Treatment of Fibrodysplasia Ossificans Progressiva
AU2016219170B2 (en) * 2015-02-13 2021-09-09 Sorrento Therapeutics, Inc. Antibody therapeutics that bind CTLA4
EP3288976B1 (fr) 2015-04-29 2020-04-08 Regeneron Pharmaceuticals, Inc. Traitement de la fibrodysplasie ossifiante progressive

Also Published As

Publication number Publication date
PT3191512T (pt) 2019-09-26
CN107106648B (zh) 2021-06-11
NZ730773A (en) 2022-07-01
KR20170052666A (ko) 2017-05-12
CA2960950A1 (fr) 2016-03-17
CL2018002962A1 (es) 2018-12-28
CY1122188T1 (el) 2020-11-25
TWI688402B (zh) 2020-03-21
ZA201702112B (en) 2018-05-30
PL3191512T3 (pl) 2020-01-31
IL251063B (en) 2022-08-01
CL2017000603A1 (es) 2017-10-06
JP2017528476A (ja) 2017-09-28
WO2016039796A3 (fr) 2016-06-16
HUE046558T2 (hu) 2020-03-30
LT3191512T (lt) 2019-09-10
MY179654A (en) 2020-11-11
WO2016039796A2 (fr) 2016-03-17
SG10201902175RA (en) 2019-04-29
DK3191512T3 (da) 2019-08-12
CA2960950C (fr) 2023-03-14
SI3191512T1 (sl) 2019-09-30
AU2015315829A1 (en) 2017-04-27
HRP20191929T1 (hr) 2020-01-10
MA40621A (fr) 2017-07-19
RS59412B1 (sr) 2019-11-29
JP6560341B2 (ja) 2019-08-14
ME03541B (fr) 2020-07-20
EP3191512A2 (fr) 2017-07-19
TW201625302A (zh) 2016-07-16
BR112017004812A2 (pt) 2017-12-12
MX2017003175A (es) 2017-06-06
IL251063A0 (en) 2017-04-30
KR102564079B1 (ko) 2023-08-08
US20180111983A1 (en) 2018-04-26
US11407822B2 (en) 2022-08-09
CN107106648A (zh) 2017-08-29
ES2739605T3 (es) 2020-02-03
EP3604335A1 (fr) 2020-02-05
US20160075772A1 (en) 2016-03-17
US20200115440A1 (en) 2020-04-16
MA40621B1 (fr) 2019-11-29
EP3191512B1 (fr) 2019-07-24
AU2015315829B2 (en) 2021-05-27

Similar Documents

Publication Publication Date Title
ZA201702112B (en) Treatment of fibrodysplasia ossificans progressiva
IL268446A (en) 5-chloro-2-difluoromethoxyphenyl pyrazolopyrimidine compounds that are jak inhibitors
ZA201700880B (en) Polymorphs of selinexor
ZA201700676B (en) Flexible configuration of harq process feedback
SG11201605989QA (en) Method of configuring walls
GB201405597D0 (en) Production of cryptographic signatures
HU4602U (en) Set of saggar assembly
GB2525930B (en) Method of authentication
PT3167068T (pt) Controlo de processos de conversão de monóxido de carbono em biorreatores
GB201409734D0 (en) Controlled alton source
IL285700A (en) 21- Hydroxylation of steroids
HK1251898A1 (zh) 進行性骨化性纖維發育不良的治療
PL3194456T3 (pl) Zawierające fosfor środki zmniejszające palność
HU4603U (en) Set of saggar assembly
GB201400500D0 (en) Modular mounting system for components of heating chamber
ZA201608307B (en) Process for the purification of l-alpha-glycerophosphorylcholine
HK1231658A1 (zh) 連接設備系統
HK1216381A1 (zh) 烤箱元件控制器
HUP1400461A2 (en) Process of bioremediation
GB201408448D0 (en) Reaction chamber
GB201406559D0 (en) Induction of neurogenesis